REG - Medpal AI PLC - Completion of Acquisition

Medpal AIAnnouncement

Today 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260216:nRSP0444Ta&default-theme=true

RNS Number : 0444T  Medpal AI PLC  16 February 2026

16 February 2026

Medal AI plc

("MedPal AI" or the "Company")

Completion of Acquisition of Universal Pharmacy assets and Expansion of
Robotic Distribution Facility in Swaffham

Medpal AI plc (AIM: MPAL, Frankfurt: Z1N), the AI-powered pharmacy and
healthcare services group, is pleased to announce the successful completion of
its acquisition of key assets (the "Acquisition") from Universal Pharmacy Ltd
(in administration) on 13 February 2026. The Acquisition was undertaken
through the Company's wholly owned subsidiary, MedPal Limited, and was
originally announced on 16 September 2025. Completion of the transaction was
conditional, inter alia, on MedPal Limited obtaining approval from NHS England
of its pharmacy licence application, confirming fitness to practice and change
of ownership in respect of the NHS pharmacy contract previously held by
Universal Pharmacy Limited.

The licence was approved on 4 November 2025 and the pharmacy is now fully
operational under Medpal Limited's ownership. Consideration for the
Acquisition comprised an initial payment of £15,000 followed by a final
payment of £30,000 on completion.

In conjunction with the Acquisition, the pharmacy premises have been expanded
to encompass Units 21, 23, and 25 at Ecotech Innovation Business Park, Turbine
Way, Swaffham, Norfolk PE37 7XD. This represents a tripling of the facility's
footprint, creating one of the UK's most advanced robotic distribution hubs
for pharmaceutical services. The expansion includes:

·      Assignment of existing leases for Units 23 and 25 (previously
operated by Universal Pharmacy Ltd); and

·      A new 10-year lease (with a break option in 2029) for Unit 21,
adjacent to the existing sites.

The enlarged facility is now structured to operate 24/7 with a capacity to
handle over 100,000 prescription items per month with automated dispensing,
order fulfilment, and nationwide delivery of prescription and over-the-counter
medications. It aligns with the Company's strategy to leverage AI and robotics
to improve efficiency, reduce costs, and expand its market share in the
growing UK pharmacy sector.

This transaction further advances Medpal AI's vertically integrated healthcare
model, as outlined in the Company's announcement
(https://www.londonstockexchange.com/news-article/MPAL/vertically-integrated-healthcare-model/17453381)
of 10 February 2026. By securing the NHS contract, integrating the pharmacy
operations  acquired from Universal Pharmacy Ltd, and tripling the Swaffham
robotic hub's capacity, the Company now has enhanced end-to-end control - from
AI-driven clinical services and consultations to automated dispensing,
fulfilment, and patient delivery. This strengthens revenue capture at every
step of the care pathway, improves operational margins, and positions Medpal
AI to deliver scalable, cost-effective healthcare solutions across the UK.

Jason Drummond, CEO of Medpal AI, commented:

"We are delighted to have completed this acquisition and facility expansion.
The integration of Universal Pharmacy's operations into our Medpal Limited
subsidiary, combined with the tripling of our Swaffham robotic hub, directly
supports our vertically integrated model and positions us strongly for
accelerated growth. This milestone underscores our commitment to building a
scalable, technology-driven pharmacy platform that delivers better outcomes
for patients, prescribers, and the NHS."

 

 

This announcement contains inside information for the purposes of Article 7 of
EU Regulation 596/2014 (which forms part of domestic UK law pursuant to the
European Union (Withdrawal) Act 2018). The Directors of the Company are
responsible for the contents of this announcement.

Enquiries:

 MedPal AI plc

 Jason Drummond, Chief Executive Officer     Via Square1 Consulting

 Cairn Financial Advisers LLP                +44 (0) 20 7213 0880

 Louise O'Driscoll/Jo Turner

 Clear Capital Markets Limited               +44 (0) 20 3869 6080

 Bob Roberts

 Square1 Consulting                          +44 (0) 20 7929 5599

 David Bick                                  +44 (0) 7831 381201

 

 

 

Notes to Editors: Medpal AI plc is an AIM-listed company (with a dual listing
on the Frankfurt Stock Exchange) focused on transforming pharmacy services
through AI, automation, and digital health solutions. The Company operates a
network of pharmacies and distribution facilities, with a core emphasis on
robotic dispensing technology to enhance accuracy, speed, and accessibility of
medicines.

This announcement contains inside information for the purposes of Article 7 of
the Market Abuse Regulation (EU) 596/2014 as it forms part of UK domestic law
by virtue of the European Union (Withdrawal) Act 2018 ("MAR"). Upon the
publication of this announcement via a Regulatory Information Service ("RIS"),
this inside information is now considered to be in the public domain.

The directors of the Company take responsibility for this announcement.

Forward Looking Statements

This announcement contains forward-looking statements relating to expected or
anticipated future events and anticipated results that are forward-looking in
nature and, as a result, are subject to certain risks and uncertainties, such
as general economic, market and business conditions, competition for qualified
staff, the regulatory process and actions, technical issues, new legislation,
uncertainties resulting from potential delays or changes in plans,
uncertainties resulting from working in a new political jurisdiction,
uncertainties regarding the results of exploration, uncertainties regarding
the timing and granting of prospecting rights, uncertainties regarding the
timing and granting of regulatory and other third party consents and
approvals, uncertainties regarding the Company's or any third party's ability
to execute and implement future plans, and the occurrence of unexpected
events.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  ACQGPUWUPUPQGBA



            Copyright 2019 Regulatory News Service, all rights reserved